<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="landscape of randomized placebo controlled trials utilizing probiotic interventions as" exact="migraine" post="prophylaxis. Searches were conducted of scientific databases including PubMed,"/>
 <result pre="a dichotomy of results—one trial reported no significant change in" exact="migraine" post="frequency and intensity, while the second trial reported highly"/>
 <result pre="a series of recommendations for future probiotic–migraine research are included." exact="migraine" post="probiotics prophylaxis gut–brain axis systematic review 1. Introduction Migraine"/>
 <result pre="absence of aura symptoms (~70%) and (2) monthly burden: episodic" exact="migraine" post="(&amp;lt;15 headache days per month; &amp;gt;90%) and chronic migraine"/>
 <result pre="episodic migraine (&amp;lt;15 headache days per month; &amp;gt;90%) and chronic" exact="migraine" post="(15 or more headache days per month; &amp;lt;10%) ["/>
 <result pre="female sex hormones during the reproductive years. The pathophysiology of" exact="migraine" post="is complex and involves genetic, metabolic, and hormonal elements"/>
 <result pre="the brain, and indeed have a recently suggested role in" exact="migraine" post="headaches [ 6]. The microbiome–gut–brain axis consists of at"/>
 <result pre="that there are low levels of 5-HT before and between" exact="migraine" post="attacks, with high levels being seen during attacks, the"/>
 <result pre="Stress has been identified as the most common trigger for" exact="migraine" post="attacks [ 17], and evidence suggests there may be"/>
 <result pre="a well-documented pro-inflammatory effect. The relevance of lipopolysaccharides (LPS) to" exact="migraine" post="headache is highlighted by evidence that it sensitizes pain"/>
 <result pre="sensitizes pain receptors in trigeminal sensory neurons (those involved in" exact="migraine" post="headaches) [ 19]. Research has identified that probiotics are"/>
 <result pre="may explain an additional mechanism by which they can influence" exact="migraine" post="headaches. The primary goals of migraine treatments include relieving"/>
 <result pre="which they can influence migraine headaches. The primary goals of" exact="migraine" post="treatments include relieving pain, restoring function, and reducing headache"/>
 <result pre="restoring function, and reducing headache frequency with current treatments for" exact="migraine" post="centering on decreasing the frequency, severity, and duration of"/>
 <result pre="migraine centering on decreasing the frequency, severity, and duration of" exact="migraine" post="attacks [ 22, 23, 24]. Recently, probiotics have become"/>
 <result pre="aims to discuss the effectiveness of probiotic interventions in treating" exact="migraine" post="symptoms based on published randomized controlled trials. 2. Materials"/>
 <result pre="controlled trials of adult male and female participants diagnosed with" exact="migraine" post="based on defined clinical criteria, who were administered any"/>
 <result pre="control group or placebo with results reported for frequency of" exact="migraine" post="attacks and/or severity of migraine attacks at least at"/>
 <result pre="results reported for frequency of migraine attacks and/or severity of" exact="migraine" post="attacks at least at baseline and at the end"/>
 <result pre="the following symptoms were extracted from the included articles: demographics," exact="migraine" post="diagnostic criteria, migraine symptoms (severity, frequency, duration), quality of"/>
 <result pre="were extracted from the included articles: demographics, migraine diagnostic criteria," exact="migraine" post="symptoms (severity, frequency, duration), quality of life or disability"/>
 <result pre="or breastfeeding. In addition, de Roos excluded patients with chronic" exact="migraine" post="or with inflammatory bowel disease, while Martami excluded patients"/>
 <result pre="in CRP seen in the probiotic arm of the chronic" exact="migraine" post="(CM) group in the Martami study. Both studies used"/>
 <result pre="study. Both studies used daily diaries to obtain information about" exact="migraine" post="frequency and intensity; neither of which were validated. Migraine"/>
 <result pre="entirely comparable and suggest that Martami’s cohort had more severe" exact="migraine" post="attacks, as the total average at baseline was higher"/>
 <result pre="and 6.4 in placebo). De Roos demonstrated no change in" exact="migraine" post="symptoms after the intervention, while the other study reported"/>
 <result pre="intervention, while the other study reported significant improvement in the" exact="migraine" post="symptoms in both chronic and episodic migraine sufferers. Frequency"/>
 <result pre="improvement in the migraine symptoms in both chronic and episodic" exact="migraine" post="sufferers. Frequency of migraine attacks (migraine days) at baseline"/>
 <result pre="symptoms in both chronic and episodic migraine sufferers. Frequency of" exact="migraine" post="attacks (migraine days) at baseline were reported based on"/>
 <result pre="that the de Roos cohort had a similar frequency of" exact="migraine" post="attacks when compared to the episodic group in Martami’s"/>
 <result pre="paper. However, reporting of the effect of the intervention on" exact="migraine" post="days was different between the studies. De Roos’ reporting"/>
 <result pre="18 days in the probiotic arm and 0 to 15" exact="migraine" post="days in the placebo group. This was consistent with"/>
 <result pre="group. This was consistent with the results reported for the" exact="migraine" post="disability assessment test (MIDAS) questionnaire by the same author"/>
 <result pre="disability assessment test (MIDAS) questionnaire by the same author (total" exact="migraine" post="days over a 3 month period) suggesting 15 migraine"/>
 <result pre="(total migraine days over a 3 month period) suggesting 15" exact="migraine" post="days over 3 months both at baseline and at"/>
 <result pre="trial. Martami reported the effect of the intervention on the" exact="migraine" post="days at the end of the trial. Intervention in"/>
 <result pre="Roos trial did not translate into a significant reduction in" exact="migraine" post="days at any point of the trial, while Martami"/>
 <result pre="of the trial, while Martami demonstrated a reduction of 9.6" exact="migraine" post="days in the CM group and 2.6 days reduction"/>
 <result pre="the CM group and 2.6 days reduction in the episodic" exact="migraine" post="(EM) group, which was significantly different to results seen"/>
 <result pre="de Roos showed no difference in the median number of" exact="migraine" post="days between probiotic and placebo arms. The change in"/>
 <result pre="between probiotic and placebo arms. The change in severity of" exact="migraine" post="attacks was also different between the studies. Martami found"/>
 <result pre="the studies. Martami found a reduction in the severity of" exact="migraine" post="episodes in EM (mean change −2.1 points) and in"/>
 <result pre="in de Roos’ study. De Roos did not report on" exact="migraine" post="duration (despite the fact that it was a question"/>
 <result pre="question included in the daily diary), whereas Martami reported that" exact="migraine" post="duration remained unchanged in the EM cohort, while CM"/>
 <result pre="while CM patients had a significant decrease in duration of" exact="migraine" post="attacks compared to placebo (−0.59 hours). De Roos included"/>
 <result pre="arm had a reduction of 2 or more days in" exact="migraine" post="frequency from baseline to the end of the trial;"/>
 <result pre="recent years, the role played by the gut microbiota in" exact="migraine" post="pathophysiology remains to be convincingly established. This situation is"/>
 <result pre="number of human clinical studies investigating the gut microbiota in" exact="migraine" post="patients and how its manipulation might impact on its"/>
 <result pre="reproducible? The exact nature the gut microbiome of the typical" exact="migraine" post="patient is yet to be fully understood. Analysis of"/>
 <result pre="publication, Georgescu et al. demonstrated greater levels of dysbiosis in" exact="irritable bowel syndrome" post="(IBS) patients with migraine when compared to IBS controls"/>
 <result pre="levels of dysbiosis in irritable bowel syndrome (IBS) patients with" exact="migraine" post="when compared to IBS controls without a history of"/>
 <result pre="migraine when compared to IBS controls without a history of" exact="migraine" post="[ 32]. While these two papers illustrate the need"/>
 <result pre="that differences exist in the microbiome of patients that experience" exact="migraine" post="when compared to migraine-free controls. Neither of the randomized"/>
 <result pre="[ 27], failed to demonstrate a statistically significant change in" exact="migraine" post="frequency between the probiotic intervention group and placebo. In"/>
 <result pre="et al. [ 28], demonstrated an approximately 40% reduction in" exact="migraine" post="frequency in the probiotic groups. In their study of"/>
 <result pre="patients, Martami et al. [ 28] saw a reduction in" exact="migraine" post="frequency of 2.6 days per month compared to placebo."/>
 <result pre="a recent Cochrane review and meta-analysis of topiramate as a" exact="migraine" post="prophylaxis for EM patients, Linde et al. [ 33]"/>
 <result pre="Martami study demonstrates a statistically and clinically significant reduction in" exact="migraine" post="frequency in both EM and CM patients given the"/>
 <result pre="the Martami study. This particular population saw large reductions in" exact="migraine" post="frequency, but counter-intuitively saw a statistically significant increase in"/>
 <result pre="the microorganisms included here might be more—or less—effective at improving" exact="migraine" post="symptoms. Microbiome and probiotic research is conducted at strain"/>
 <result pre="lines of evidence hint at the role of bacteria in" exact="migraine" post="pathogenesis, however, which elements are more, or less, important"/>
 <result pre="example, multiple lines of evidence point towards an overlap between" exact="migraine" post="and certain GI diagnoses, suggesting that an impaired gut"/>
 <result pre="an impaired gut barrier function may play a role in" exact="migraine" post="pathogenesis [ 39]. Impaired gut barrier function can lead"/>
 <result pre="Equally important is consideration of the role of serotonin in" exact="migraine" post="pathophysiology—and the role of the gut microbiota in producing"/>
 <result pre="serotonin; both within the gut and within the CNS. Intra-ictally," exact="migraine" post="is known to be a low serotonin state and"/>
 <result pre="suggests that depletion of tryptophan (the precursor to serotonin) exacerbates" exact="migraine" post="symptoms [ 40]. Multiple probiotic strains produce serotonin or"/>
 <result pre="both with other microbiome interventions and also with conventional pharmacological" exact="migraine" post="studies. Based on the studies conducted to date, the"/>
 <result pre="as shown in Table 3, could be adopted for future" exact="migraine" post="studies. 5. Conclusions With nearly 70 trials of probiotics"/>
 <result pre="between studies and between probiotic and conventional pharmacological interventions for" exact="migraine" post="prophylaxis. Supplementary Materials The following are available online at"/>
 <result pre="criteria ICHD-II ICHD-III beta ICHD-III beta Migraine subtypes included Episodic" exact="migraine" post="Chronic migraine Episodic migraine Probiotic Ecologic Barrier, Winclove Bifidobacterium"/>
 <result pre="ICHD-III beta ICHD-III beta Migraine subtypes included Episodic migraine Chronic" exact="migraine" post="Episodic migraine Probiotic Ecologic Barrier, Winclove Bifidobacterium bifidum W23"/>
 <result pre="ICHD-III beta Migraine subtypes included Episodic migraine Chronic migraine Episodic" exact="migraine" post="Probiotic Ecologic Barrier, Winclove Bifidobacterium bifidum W23 Bifidobacterium lactis"/>
 <result pre="jcm-08-01441-t003_Table 3 Table 3 Recommendations for future probiotic trials in" exact="migraine" post="sufferers. Recommendations for future probiotic trials in migraine sufferers"/>
 <result pre="trials in migraine sufferers. Recommendations for future probiotic trials in" exact="migraine" post="sufferers Exclusion criteria Standardized exclusion criteria: use of medications"/>
 <result pre="Inclusion criteria Studies should explicitly focus on chronic or episodic" exact="migraine" post="sufferers and clearly indicate which group was studied. Studies"/>
 <result pre="clearly indicate which group was studied. Studies should focus on" exact="migraine" post="with aura and without aura and clearly indicate which"/>
 <result pre="cessation effects starts to diminish. General Use of validated standardized" exact="migraine" post="symptom questionnaires/diaries for recording of migraine frequency (frequency of"/>
 <result pre="Use of validated standardized migraine symptom questionnaires/diaries for recording of" exact="migraine" post="frequency (frequency of migraine onsets), duration (hours), and severity"/>
 <result pre="migraine symptom questionnaires/diaries for recording of migraine frequency (frequency of" exact="migraine" post="onsets), duration (hours), and severity (validated scale or a"/>
 <result pre="the effect of intervention in groups with different severities of" exact="migraine" post="symptoms. Inclusion of standard reporting metrics, such as 50%"/>
 <result pre="and non-responders, with explicit definition of responders (e.g., reduction of" exact="migraine" post="duration by over 2 days per month). Preferably, microbiome"/>
</results>
